常染色体显性及散发性阿尔茨海默病中白质高信号病因学研究
该队列研究纳入1141名参与者共3960次MRI检查,评估神经变性、脑实质淀粉样变及血管淀粉样变与白质高信号的关系,发现白质高信号增加与神经变性和淀粉样变相关,而与系统性血管风险无关,且可能为脑微出血出现前的早期血管淀粉样变信号。
要点
- 白质高信号增加与灰质体积下降、脑实质淀粉样变及脑微出血相关。
- 在常染色体显性及晚发型阿尔茨海默病中,白质高信号与系统性血管风险无关。
- 基线无脑微出血者白质高信号体积较大与随访中新发脑微出血相关(HR 2.63)。
核心结论
- 研究提示阿尔茨海默病中白质高信号体积增加与神经变性及脑实质和血管淀粉样变相关,而与系统性血管风险升高无关。
- 白质高信号体积增加可能是脑微出血出现前血管淀粉样变的早期标志。
研究设计与样本
- 队列研究,使用3项纵向队列研究数据:常染色体显性阿尔茨海默病网络(DIAN,2010年2月至2020年3月)、阿尔茨海默病神经影像学倡议(ADNI,2007年7月至2021年9月)和哈佛老龄脑研究(HABS,2010年9月至2019年12月)。
- 共纳入1141名参与者,包括DIAN中252名致病基因变异携带者(平均[标准差]年龄38.4[11.2]岁,女性137名[54%])、ADNI中571名老年人(平均[标准差]年龄72.8[7.3]岁,女性274名[48%])和HABS中318名老年人(平均[标准差]年龄72.4[7.6]岁,女性194名[61%])。
- 共分析3960次MRI检查数据。
主要发现
- 有脑微出血者白质高信号体积纵向增加大于无脑微出血者(DIAN:t=3.2[P=.001];ADNI:t=2.7[P=.008])。
- 白质高信号纵向增加与灰质体积纵向下降相关(DIAN:t=-3.1[P=.002];ADNI:t=-5.6[P<.001];HABS:t=-2.2[P=.03])。
- 白质高信号纵向增加在年龄较大者中更大(DIAN:t=6.8[P<.001];ADNI:t=9.1[P<.001];HABS:t=5.4[P<.001])。
- 在常染色体显性及晚发型阿尔茨海默病患者中,校正年龄、灰质体积、脑微出血存在和淀粉样负荷后,白质高信号与系统性血管风险无关联(DIAN:t=0.7[P=.40];ADNI:t=0.6[P=.50];HABS:t=1.8[P=.06])。
- 基线无脑微出血的老年人中,白质高信号体积较大与随访期间脑微出血发生相关(Cox比例风险回归模型风险比2.63;95%CI 1.72-4.03;P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Increased white matter hyperintensity (WMH) volume is a common magnetic resonance imaging (MRI) finding in both autosomal dominant Alzheimer disease (ADAD) and late-onset Alzheimer disease (LOAD), but it remains unclear whether increased WMH along the AD continuum is reflective of AD-intrinsic processes or secondary to elevated systemic vascular risk factors. OBJECTIVE: To estimate the associations of neurodegeneration and parenchymal and vessel amyloidosis with WMH accumulation and investigate whether systemic vascular risk is associated with WMH beyond these AD-intrinsic processes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from 3 longitudinal cohort studies conducted in tertiary and community-based medical centers-the Dominantly Inherited Alzheimer Network (DIAN; February 2010 to March 2020), the Alzheimer's Disease Neuroimaging Initiative (ADNI; July 2007 to September 2021), and the Harvard Aging Brain Study (HABS; September 2010 to December 2019). MAIN OUTCOME AND MEASURES: The main outcomes were the independent associations of neurodegeneration (decreases in gray matter volume), parenchymal amyloidosis (assessed by amyloid positron emission tomography), and vessel amyloidosis (evidenced by cerebral microbleeds [CMBs]) with cross-sectional and longitudinal WMH. RESULTS: Data from 3960 MRI sessions among 1141 participants were included: 252 pathogenic variant carriers from DIAN (mean [SD] age, 38.4 [11.2] years; 137 [54%] female), 571 older adults from ADNI (mean [SD] age, 72.8 [7.3] years; 274 [48%] female), and 318 older adults from HABS (mean [SD] age, 72.4 [7.6] years; 194 [61%] female). Longitudinal increases in WMH volume were greater in individuals with CMBs compared with those without (DIAN: t = 3.2 [P = .001]; ADNI: t = 2.7 [P = .008]), associated with longitudinal decreases in gray matter volume (DIAN: t = -3.1 [P = .002]; ADNI: t = -5.6 [P < .001]; HABS: t = -2.2 [P = .03]), greater in older individuals (DIAN: t = 6.8 [P < .001]; ADNI: t = 9.1 [P < .001]; HABS: t = 5.4 [P < .001]), and not associated with systemic vascular risk (DIAN: t = 0.7 [P = .40]; ADNI: t = 0.6 [P = .50]; HABS: t = 1.8 [P = .06]) in individuals with ADAD and LOAD after accounting for age, gray matter volume, CMB presence, and amyloid burden. In older adults without CMBs at baseline, greater WMH volume was associated with CMB development during longitudinal follow-up (Cox proportional hazards regression model hazard ratio, 2.63; 95% CI, 1.72-4.03; P < .001). CONCLUSIONS AND RELEVANCE: The findings suggest that increased WMH volume in AD is associated with neurodegeneration and parenchymal and vessel amyloidosis but not with elevated systemic vascular risk. Additionally, increased WMH volume may represent an early sign of vessel amyloidosis preceding the emergence of CMBs.
引用
- Shirzadi Z, Schultz SA, Yau WW, et al. Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease. JAMA Neurol. 2023. PMID: 37843849. doi:10.1001/jamaneurol.2023.3618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。